Form 8-K - Current report:
SEC Accession No. 0001213900-25-043730
Filing Date
2025-05-15
Accepted
2025-05-15 08:35:29
Documents
15
Period of Report
2025-05-15
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0242253-8k_adial.htm   iXBRL 8-K 27162
2 PRESS RELEASE ISSUED BY ADIAL PHARMACEUTICALS, INC., DATED MAY 15, 2025 ea024225301ex99-1_adial.htm EX-99.1 20661
6 GRAPHIC image_001.jpg GRAPHIC 3998
  Complete submission text file 0001213900-25-043730.txt   234106

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE adil-20250515.xsd EX-101.SCH 3005
4 XBRL LABEL FILE adil-20250515_lab.xml EX-101.LAB 34239
5 XBRL PRESENTATION FILE adil-20250515_pre.xml EX-101.PRE 22352
17 EXTRACTED XBRL INSTANCE DOCUMENT ea0242253-8k_adial_htm.xml XML 3657
Mailing Address 1180 SEMINOLE TRAIL SUITE 495 CHARLOTTESVILLE VA 22901
Business Address 1180 SEMINOLE TRAIL SUITE 495 CHARLOTTESVILLE VA 22901 434-422-9800
ADIAL PHARMACEUTICALS, INC. (Filer) CIK: 0001513525 (see all company filings)

EIN.: 800667150 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38323 | Film No.: 25948944
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)